non-immunogenic staphylokinase

Phase 3Protein / enzyme

non-immunogenic staphylokinase is one of 30 small molecule programs targeting Ischemic Stroke, Acute. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic Stroke, AcuteRecruiting

Pulmonary EmbolismRecruiting

Ischemic Stroke, AcutePhase 3

Recruiting

Pulmonary EmbolismPhase 3

Recruiting

Competition

Competitive Landscape

28 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Activase

Roche

Approved

7 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

1 4

Innohep

Jazz Pharmaceuticals

Approved

1 5

Xarelto

WWim Janssens

Approved

8 6

Coumadin

AAbbott

Approved

6 7

Voltaren

Savaysa

Opsumit

Pradaxa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Pulmonary Embolism

NCT06362746

Q1 2029

Phase 3Recruiting

Ischemic Stroke, Acute

NCT07324837

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)

Completed·SSupergene, LLC··NCT06707987·23,250 enrolled

Pulmonary Embolism1 trial

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Recruiting·SSupergene, LLC·Phase 3·NCT06362746·486 enrolled

Ischemic Stroke, Acute1 trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of the Recombinant Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset (FRIDA-CT)

Recruiting·SSupergene, LLC·Phase 3·NCT07324837·990 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for non-immunogenic staphylokinase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — non-immunogenic staphylokinase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for non-immunogenic staphylokinase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Supergene, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: SSupergene, LLC

non-immunogenic staphylokinase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Ischemic stroke1 trial

Pulmonary Embolism1 trial

Ischemic Stroke, Acute1 trial

References

Drug Info

Quick Facts

Related News